HOME>News & Media
Innovation today, healthier tomorrows


Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.

A wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., Sunovion was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 DSPA 2009 Press Releases

 Date  Title
11/9/15 Sunovion and the COPD Foundation Launch Reel COPD to Support Family Caregivers
10/19/15 Sunovion to Present Health Outcomes Data Supporting Brovana® (arformoterol tartrate) Inhalation Solution in Patients with COPD at the 2015 American College of Chest Physicians Annual Meeting
10/15/15 Sunovion Celebrates Five-Year Anniversary Milestone
10/5/15 Demi Lovato, Sunovion and Leading Advocacy Organizations Call on Americans to Join Be Vocal Initiative by Speaking Up for Mental Health
8/28/15 Sunovion Announces FDA Approval of a New Indication for Aptiom® (eslicarbazepine acetate) as Monotherapy for Partial Onset Seizures
8/21/15 Sunovion Pharmaceuticals Inc. Employees Contributed More Than 2,600 Volunteer Hours to Local Organizations during Fourth Annual Community Service Day
5/28/15 Demi Lovato Joins Forces with Sunovion and Leading Mental Health Advocacy Organizations to Launch Be Vocal: Speak Up for Mental Health
5/20/15 Sunovion Announces Health Outcomes Data that Support the Consideration of Brovana® (arformoterol tartrate) Inhalation Solution for the Maintenance Treatment of COPD at the American Thoracic Society (ATS) 2015 Annual Meeting
5/19/15 Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda® (lurasidone HCl) in First Placebo-Controlled Trial of Patients with Major Depressive Disorder with Mixed (Subsyndromal Hypomanic) Features
5/6/15 Sunovion to Present New Clinical Analysis and Health Outcomes Data Supporting Use of BROVANA in Patients with Moderate-to-Severe COPD at the 110th American Thoracic Society (ATS) Annual Meeting
4/14/15 Sunovion Pharmaceuticals Inc. to Present Data on Aptiom® (eslicarbazepine acetate) at 67th American Academy of Neurology Annual Meeting
3/31/15 New Post-hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia
3/30/15 Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA® ▼ (lurasidone) at the 23rd European Congress of Psychiatry
2/25/15 Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
1/14/15 Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda®
1/7/15 Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial Onset Seizures